Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.514
+0.064 (4.38%)
At close: May 8, 2026, 4:00 PM EDT
1.410
-0.104 (-6.84%)
Pre-market: May 11, 2026, 5:52 AM EDT

APUS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
10.281.280.650.270.53
Research & Development
1.63-0.10.370.49
Total Operating Expenses
11.911.280.750.641.02
Operating Income
-11.91-1.28-0.75-0.64-1.02
Interest Income
0.1100.01--
Interest Expense
-0.28-0.12-0.04-0.03-0.01
Other Non-Operating Income (Expense)
6.09----
Total Non-Operating Income (Expense)
5.91-0.11-0.03-0.03-0.01
Pretax Income
-6-1.39-0.78-0.67-1.03
Net Income
-6-1.39-0.78-0.67-1.03
Net Income to Common
-6-1.39-0.78-0.67-1.03
Shares Outstanding (Basic)
118544
Shares Outstanding (Diluted)
118544
Shares Change (YoY)
37.68%71.89%19.55%--
EPS (Basic)
-0.55-0.18-0.17-0.18-0.26
EPS (Diluted)
-0.55-0.18-0.17-0.18-0.26
Shares Outstanding
12.587.97.93.853.85
Free Cash Flow
-8.98-0.73-0.63-0.45-0.82
Free Cash Flow Per Share
-0.83-0.09-0.14-0.12-0.21
EBITDA
-11.91-1.28-0.75-0.64-1.02
EBIT
-11.91-1.28-0.75-0.64-1.02
Updated May 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q